Trial Profile

The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telbivudine (Primary)
Indications Chronic hepatitis; Hepatitis B; Kidney disorders; Renal impairment
Focus Therapeutic Use

Most Recent Events

26 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
03 Feb 2015 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019 as reported by ClinicalTrials.gov record.
03 Feb 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com